Bladder Pain Syndrome: US FDA Outlines A Different Approach To Personalized Medicine
Executive Summary
US FDA is following through on defining interstitial cystitis and bladder pain syndrome as a single condition – a move that runs counter to the trend towards more targeted, mechanistic definitions of disease. But the agency also offers a unique idea for endpoints that are truly personalized.